
Neuland Laboratories has recently informed exchanges that its Board has approved a ₹342 crore capital expenditure plan to boost its manufacturing capabilities and meet growing demand.
Key Projects:
- Unit 1 – Peptide Synthesizers Expansion
- Capacity: Increase from 0.5 KL to 6.87 KL.
- Investment: ₹254 crore (including GST).
- Funding: Borrowings and internal accruals.
- Completion Target: FY27.
- Purpose: Scale peptide manufacturing for CMS and GDS businesses.
- Unit 3 – Capacity Addition
- Capacity: Additional 52 KL to existing 321 KL.
- Investment: ₹88 crore (including GST).
- Funding: Internal accruals.
- Completion Target: 15-18 months.
- Purpose: Address growing customer demand.
With 15 years of expertise in peptide technology, Neuland Labs is set to capitalize on niche opportunities by building a new multi-product peptide block at Unit 1. This expansion aligns with the company’s long-term growth strategy, enhancing capabilities for CMS and GDS customers.